Lower GI 2017

NSABP R-04 establishes capecitabine as standard of care

5-FU vs capecitabine

3-year local-regional tumour event rates (11.2% vs 11.8%),

5-year DFS (66.4% vs 67.7%)

5-year OS (79.9% vs 80.8%);

03/01/13